November 19th, 2026Real-World Lecanemab Outcomes in Alzheimer Disease, Reported at 3 YearsLeqembi shows lower progression rate in Alzheimer disease over 3 years, shows new data.Read more
November 19th, 2026sNDA Submitted: Caplyta for the Treatment of Bipolar ManiaJohnson & Johnson has submitted an sNDA to the FDA for Caplyta for the treatment of bipolar mania. Read more
November 16th, 2026Morning Rounds: News From November 9-16Review news from the last week in pharmacology, legislation, and research. Read more
November 16th, 2026FDA Approves Igalmi for Agitation Associated With Schizophrenia, Schizoaffective Disorder, or Bipolar I or II DisorderThe FDA has approved dexmedetomidine (Igalmi) sublingual film for at-home use. Read more
November 13th, 2026Adopting New Voices: Supporting Nonspeaking Patients After Brain InjuryMany traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.Read more
November 13th, 2026Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and SchizophreniaReview the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.Read more
November 12th, 2026Digital Gradebook Engagement Scores May Flag Adolescents at Risk for Substance UseTeacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.Read more
November 12th, 2026Major Depressive Disorder With Mixed Features: Diagnosis and TreatmentMixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.Read more